Eagle Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Eagle Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$303K	Sell	11,201 -252,383	-96%	-$6.63M	﹤0.01%	520
2024 Q2	$6.64M	Sell	263,584 -46,575	-15%	-$1.27M	0.04%	360
2024 Q1	$9.3M	Buy	310,159 +91,060	+42%	+$3.1M	0.05%	298
2023 Q4	$8.85M	Buy	+219,099	New	+$6.58M	0.05%	288
2022 Q1	–	Sell	-265,607	Closed	-$3.86M	–	580
2021 Q4	$3.86M	Sell	265,607 -121,109	-31%	-$5.12M	0.02%	435
2021 Q3	$18.1M	Sell	386,716 -119,233	-24%	-$6.39M	0.08%	229
2021 Q2	$30.8M	Sell	505,949 -17,744	-3%	-$1.01M	0.13%	199
2021 Q1	$31.1M	Buy	523,693 +177,693	+51%	+$11.6M	0.14%	201
2020 Q4	$24.6M	Buy	+346,000	New	+$16.7M	0.14%	206

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eagle Asset Management's BBIO Position: Q3 2024 in Review

Eagle Asset Management reduced its BridgeBio Pharma (BBIO) stake by 96% in Q3 2024, selling an estimated $6.63M and leaving 11,201 shares worth $303K. The position accounts for ﹤0.01% of the portfolio, ranked #520.

Eagle Asset Management first reported a position in BBIO in Q4 2020 and has held it in 9 quarters since. The position peaked at $31.1M in Q1 2021. 253 funds tracked by Wall St. Rank hold BBIO as of Q3 2024.

Eagle Asset Management held 11,201 shares of BridgeBio Pharma worth $303K as of Q3 2024.
Eagle Asset Management sold 252,383 BridgeBio Pharma shares in Q3 2024, an estimated $6.63M.
BridgeBio Pharma made up ﹤0.01% of Eagle Asset Management's portfolio in Q3 2024, its #520 holding.
Eagle Asset Management first reported a position in BridgeBio Pharma in Q4 2020 and has held it in 9 quarters since.
Eagle Asset Management's BridgeBio Pharma position peaked at $31.1M in Q1 2021.
253 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.